×
S&P 500   3,855.11 (+0.62%)
DOW   31,110.56 (+0.46%)
QQQ   290.08 (+1.09%)
AAPL   143.57 (+1.42%)
MSFT   267.17 (+1.64%)
META   170.29 (+1.25%)
GOOGL   2,293.41 (+1.24%)
AMZN   115.14 (+1.44%)
TSLA   697.89 (-0.19%)
NVDA   152.78 (+2.10%)
NIO   20.79 (-6.27%)
BABA   119.15 (-0.82%)
AMD   76.02 (+1.09%)
MU   57.88 (+2.03%)
CGC   2.68 (-1.11%)
T   21.17 (+0.09%)
GE   61.94 (-0.15%)
F   11.17 (-0.27%)
DIS   96.70 (-0.49%)
AMC   12.59 (-1.49%)
PFE   52.44 (+1.55%)
PYPL   73.78 (-0.83%)
NFLX   185.16 (-0.39%)
S&P 500   3,855.11 (+0.62%)
DOW   31,110.56 (+0.46%)
QQQ   290.08 (+1.09%)
AAPL   143.57 (+1.42%)
MSFT   267.17 (+1.64%)
META   170.29 (+1.25%)
GOOGL   2,293.41 (+1.24%)
AMZN   115.14 (+1.44%)
TSLA   697.89 (-0.19%)
NVDA   152.78 (+2.10%)
NIO   20.79 (-6.27%)
BABA   119.15 (-0.82%)
AMD   76.02 (+1.09%)
MU   57.88 (+2.03%)
CGC   2.68 (-1.11%)
T   21.17 (+0.09%)
GE   61.94 (-0.15%)
F   11.17 (-0.27%)
DIS   96.70 (-0.49%)
AMC   12.59 (-1.49%)
PFE   52.44 (+1.55%)
PYPL   73.78 (-0.83%)
NFLX   185.16 (-0.39%)
S&P 500   3,855.11 (+0.62%)
DOW   31,110.56 (+0.46%)
QQQ   290.08 (+1.09%)
AAPL   143.57 (+1.42%)
MSFT   267.17 (+1.64%)
META   170.29 (+1.25%)
GOOGL   2,293.41 (+1.24%)
AMZN   115.14 (+1.44%)
TSLA   697.89 (-0.19%)
NVDA   152.78 (+2.10%)
NIO   20.79 (-6.27%)
BABA   119.15 (-0.82%)
AMD   76.02 (+1.09%)
MU   57.88 (+2.03%)
CGC   2.68 (-1.11%)
T   21.17 (+0.09%)
GE   61.94 (-0.15%)
F   11.17 (-0.27%)
DIS   96.70 (-0.49%)
AMC   12.59 (-1.49%)
PFE   52.44 (+1.55%)
PYPL   73.78 (-0.83%)
NFLX   185.16 (-0.39%)
S&P 500   3,855.11 (+0.62%)
DOW   31,110.56 (+0.46%)
QQQ   290.08 (+1.09%)
AAPL   143.57 (+1.42%)
MSFT   267.17 (+1.64%)
META   170.29 (+1.25%)
GOOGL   2,293.41 (+1.24%)
AMZN   115.14 (+1.44%)
TSLA   697.89 (-0.19%)
NVDA   152.78 (+2.10%)
NIO   20.79 (-6.27%)
BABA   119.15 (-0.82%)
AMD   76.02 (+1.09%)
MU   57.88 (+2.03%)
CGC   2.68 (-1.11%)
T   21.17 (+0.09%)
GE   61.94 (-0.15%)
F   11.17 (-0.27%)
DIS   96.70 (-0.49%)
AMC   12.59 (-1.49%)
PFE   52.44 (+1.55%)
PYPL   73.78 (-0.83%)
NFLX   185.16 (-0.39%)
OTCMKTS:RGRX

RegeneRx Biopharmaceuticals Stock Forecast, Price & News

$0.16
+0.01 (+6.56%)
(As of 07/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.16
$0.18
50-Day Range
$0.15
$0.22
52-Week Range
$0.10
$0.45
Volume
67,399 shs
Average Volume
30,286 shs
Market Capitalization
$23.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

RegeneRx Biopharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.31 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive RGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RegeneRx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RegeneRx Biopharmaceuticals logo

About RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Stock

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

RGRX Stock News Headlines

RGRX Real-Time Quotes
RGRX After-Hours Quotes
RegeneRx Licensee Acquired by Korean Biopharmaceutical Group
RegeneRx Issues Letter To Stockholders
RegeneRx Issues Update on ARISE-3 Trial
RegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye Trial
RegeneRx Comments on ARISE-3 Clinical Trial
RegeneRx Issues Year End Letter To Stockholders
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:RGRX
Employees
3
Year Founded
N/A

Company Calendar

Today
7/06/2022
Fiscal Year End
12/31/2022

Profitability

Net Income
$-1,600,000.00
Net Margins
-2,149.78%
Pretax Margin
-2,149.78%

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
($0.02) per share

Miscellaneous

Free Float
125,606,000
Market Cap
$23.33 million
Optionable
Not Optionable
Beta
0.38














RegeneRx Biopharmaceuticals Frequently Asked Questions

How has RegeneRx Biopharmaceuticals' stock performed in 2022?

RegeneRx Biopharmaceuticals' stock was trading at $0.16 at the start of the year. Since then, RGRX stock has increased by 1.6% and is now trading at $0.1625.
View the best growth stocks for 2022 here
.

Who are RegeneRx Biopharmaceuticals' key executives?

RegeneRx Biopharmaceuticals' management team includes the following people:
  • Dr. Allan L. Goldstein Ph.D., Founder, Chairman, Chief Scientific Officer & Chairman of Scientific Advisor Board (Age 84, Pay $90k)
  • Mr. J. J. Finkelstein, Pres, CEO & Director (Age 70, Pay $83.38k)
  • Dr. Nabila A. Turjman Ph.D., Exec. Director of Regulatory Affairs

What other stocks do shareholders of RegeneRx Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RegeneRx Biopharmaceuticals investors own include Biocept (BIOC), Fulcrum Therapeutics (FULC), Inpixon (INPX), OPKO Health (OPK), VBI Vaccines (VBIV), Vaxart (VXRT), AVEO Pharmaceuticals (AVEO), Palatin Technologies (PTN), Sorrento Therapeutics (SRNE) and Sierra Oncology (SRRA).

What is RegeneRx Biopharmaceuticals' stock symbol?

RegeneRx Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "RGRX."

How do I buy shares of RegeneRx Biopharmaceuticals?

Shares of RGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RegeneRx Biopharmaceuticals' stock price today?

One share of RGRX stock can currently be purchased for approximately $0.16.

How much money does RegeneRx Biopharmaceuticals make?

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) has a market capitalization of $23.33 million and generates $80,000.00 in revenue each year.

How many employees does RegeneRx Biopharmaceuticals have?

RegeneRx Biopharmaceuticals employs 3 workers across the globe.

How can I contact RegeneRx Biopharmaceuticals?

RegeneRx Biopharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 470, ROCKVILLE MD, 20850. The official website for RegeneRx Biopharmaceuticals is www.regenerx.com. The biopharmaceutical company can be reached via phone at (301) 208-9191, via email at info@regenerx.com, or via fax at 301-280-1996.

This page (OTCMKTS:RGRX) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.